CN102743363B - 和厚朴酚及其衍生物制备治疗马拉色菌引起皮肤疾病的制品的用途 - Google Patents
和厚朴酚及其衍生物制备治疗马拉色菌引起皮肤疾病的制品的用途 Download PDFInfo
- Publication number
- CN102743363B CN102743363B CN201110099312.9A CN201110099312A CN102743363B CN 102743363 B CN102743363 B CN 102743363B CN 201110099312 A CN201110099312 A CN 201110099312A CN 102743363 B CN102743363 B CN 102743363B
- Authority
- CN
- China
- Prior art keywords
- honokiol
- chlosma
- goods
- dermatosis
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 title claims abstract description 57
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 title claims abstract description 53
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 208000017520 skin disease Diseases 0.000 title claims abstract description 37
- 241000555676 Malassezia Species 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 25
- 206010048768 Dermatosis Diseases 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 19
- -1 hair conditioner Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000003203 everyday effect Effects 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 241001597008 Nomeidae Species 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000004530 micro-emulsion Substances 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 230000037317 transdermal delivery Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 238000009395 breeding Methods 0.000 abstract description 2
- 230000001488 breeding effect Effects 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 239000000969 carrier Substances 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000002609 medium Substances 0.000 description 9
- 208000001840 Dandruff Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 6
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 6
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 6
- 208000008742 seborrheic dermatitis Diseases 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 206010012438 Dermatitis atopic Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 229940081733 cetearyl alcohol Drugs 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 229940124274 edetate disodium Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000555688 Malassezia furfur Species 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- FKKAGFLIPSSCHT-UHFFFAOYSA-N 1-dodecoxydodecane;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC FKKAGFLIPSSCHT-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100024233 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Human genes 0.000 description 2
- 101001117267 Homo sapiens High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241001400675 Sympodium Species 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 2
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000004567 concrete Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- AOLMPVPUFVWGPN-UHFFFAOYSA-N diazanium;1-dodecoxydodecane;sulfate Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC AOLMPVPUFVWGPN-UHFFFAOYSA-N 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000008710 Amebic Dysentery Diseases 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000896292 Odontothrips loti Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 208000017448 integumentary system disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960004718 sulconazole nitrate Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110099312.9A CN102743363B (zh) | 2011-04-20 | 2011-04-20 | 和厚朴酚及其衍生物制备治疗马拉色菌引起皮肤疾病的制品的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110099312.9A CN102743363B (zh) | 2011-04-20 | 2011-04-20 | 和厚朴酚及其衍生物制备治疗马拉色菌引起皮肤疾病的制品的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102743363A CN102743363A (zh) | 2012-10-24 |
CN102743363B true CN102743363B (zh) | 2015-01-21 |
Family
ID=47024099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110099312.9A Active CN102743363B (zh) | 2011-04-20 | 2011-04-20 | 和厚朴酚及其衍生物制备治疗马拉色菌引起皮肤疾病的制品的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102743363B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018033470A1 (en) * | 2016-08-19 | 2018-02-22 | Unilever N.V. | An antimicrobial composition |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102871989B (zh) * | 2011-07-04 | 2015-06-10 | 四川大学 | 和厚朴酚或其药学上可接受的盐的新用途 |
CN104970987B (zh) * | 2014-04-11 | 2018-01-19 | 珀莱雅化妆品股份有限公司 | 一种修复过敏后受损肌肤的脂质体的制备方法 |
CN104042517B (zh) * | 2014-06-28 | 2016-08-31 | 管天球 | 一种茶油护发剂 |
CN104382760A (zh) * | 2014-12-10 | 2015-03-04 | 唯美度科技(北京)有限公司 | 一种天然去屑洗发水及其制备方法 |
BR112019003273B1 (pt) | 2016-08-19 | 2022-04-12 | Unilever Ip Holdings B.V. | Composição antimicrobiana sinérgica |
CN117941682A (zh) | 2017-12-22 | 2024-04-30 | 联合利华知识产权控股有限公司 | 抗微生物组合物 |
CN110585265B (zh) * | 2019-10-13 | 2021-10-08 | 郭哲文 | 一种马拉色菌抑制剂 |
CN112675087A (zh) * | 2020-12-31 | 2021-04-20 | 肇庆迪彩日化科技有限公司 | 一种植物抗菌抑菌头皮护理组合物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4082830B2 (ja) * | 1999-10-13 | 2008-04-30 | 株式会社東芝 | 電磁ポンプおよび同ポンプを用いた流体循環装置 |
CN101795732A (zh) * | 2007-04-19 | 2010-08-04 | 玫琳凯有限公司 | 含木兰提取物的组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2746737B2 (ja) * | 1990-07-23 | 1998-05-06 | 御木本製薬株式会社 | ニキビ用皮膚外用剤 |
JP2826268B2 (ja) * | 1994-06-14 | 1998-11-18 | メイサン商事株式会社 | 巻取り用コアの連結具 |
CN1511517A (zh) * | 2002-12-30 | 2004-07-14 | 北京大学第一医院 | 厚朴酚与和厚朴酚及其衍生物在抑制血管生成中的应用 |
-
2011
- 2011-04-20 CN CN201110099312.9A patent/CN102743363B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4082830B2 (ja) * | 1999-10-13 | 2008-04-30 | 株式会社東芝 | 電磁ポンプおよび同ポンプを用いた流体循環装置 |
CN101795732A (zh) * | 2007-04-19 | 2010-08-04 | 玫琳凯有限公司 | 含木兰提取物的组合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018033470A1 (en) * | 2016-08-19 | 2018-02-22 | Unilever N.V. | An antimicrobial composition |
Also Published As
Publication number | Publication date |
---|---|
CN102743363A (zh) | 2012-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102743363B (zh) | 和厚朴酚及其衍生物制备治疗马拉色菌引起皮肤疾病的制品的用途 | |
KR20190037229A (ko) | 상승효과적 항진균 조성물 및 그의 방법 | |
WO2017216722A2 (en) | Synergistic antifungal compositions and methods thereof | |
US20050100621A1 (en) | Dermatological compositions | |
US6964952B2 (en) | Therapeutic composition for broad spectrum dermal disease | |
CN102218048B (zh) | 厚朴酚在制备治疗马拉色菌引起皮肤病的外用制剂和日化品中应用 | |
US10561627B2 (en) | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films | |
Pandey et al. | Site-specific vesicular drug delivery system for skin cancer: a novel approach for targeting | |
JP5013753B2 (ja) | 防腐殺菌剤組成物 | |
CN110538313B (zh) | 一种广谱抗马拉色菌的天然产物组合物及应用 | |
CN103347507A (zh) | 用于治疗痤疮的褪黑激素以及抗微生物剂或抗菌剂 | |
KR20120058850A (ko) | 항염증 및 항균활성을 가지는 조성물 | |
JP5219038B2 (ja) | 皮膚角化促進剤 | |
EP2566455B1 (en) | Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies | |
KR20150072797A (ko) | 고농도 카페인을 함유하는 조성물 | |
KR100846356B1 (ko) | 파래 속 추출물을 포함하는 항진균 조성물 | |
KR100776755B1 (ko) | 생약 추출물을 함유하는 가려움증 억제 및 완화용 조성물 | |
CN102949299B (zh) | 荷叶碱或含其的植物提取物的应用 | |
JP2012162473A (ja) | N−アセチルグルコサミンを含有する組成物 | |
US20060264505A1 (en) | Dermatological compositions | |
JP2990611B2 (ja) | フケ菌発育阻害成分含有物の抽出方法 | |
JPH10175868A (ja) | 津液改善組成物 | |
JP7361448B2 (ja) | トランスグルタミナーゼ発現促進剤 | |
TW202112351A (zh) | 局部組成物及其相關方法 | |
JP4294511B2 (ja) | 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI BANGSHI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHANGHAI LAIBO BIO-CHEMICAL CO. LTD. Effective date: 20130805 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200032 XUHUI, SHANGHAI TO: 200233 XUHUI, SHANGHAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130805 Address after: 200233, room 1, building 333, No. 703, Guiping Road, Shanghai Applicant after: SHANGHAI BANGSHI BIOTECHNOLOGY CO., LTD. Address before: 200032, room 4, No. 7, Lane 703, Lingling North Road, Shanghai, Xuhui District Applicant before: Shanghai Laibo Bio-chemical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LB NATURE (SHANGHAI) CO., LTD. Free format text: FORMER OWNER: SHANGHAI BANGSHI BIOTECHNOLOGY CO., LTD. Effective date: 20150619 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150619 Address after: 200030, building 1, building 333, No. 8, Guiping Road, Shanghai, Xuhui District Patentee after: Laibo Industrial (Shanghai) Limited by Share Ltd Address before: 200233, room 1, building 333, No. 703, Guiping Road, Shanghai Patentee before: SHANGHAI BANGSHI BIOTECHNOLOGY CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 200030, building 1, building 333, No. 8, Guiping Road, Shanghai, Xuhui District Patentee after: Laibo cosmeceutical Technology (Shanghai) Limited by Share Ltd Address before: 200030, building 1, building 333, No. 8, Guiping Road, Shanghai, Xuhui District Patentee before: Laibo Industrial (Shanghai) Limited by Share Ltd |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220207 Address after: 201401 building 4, No. 1979, CHENQiao Road, Fengxian District, Shanghai Patentee after: Shengwei Pharmaceutical (Shanghai) Co.,Ltd. Address before: 8th floor, building 1, No. 333 Guiping Road, Xuhui District, Shanghai Patentee before: LB COSMECEUTICAL TECHNOLOGY Co.,Ltd. |